Cargando…

Identification of PTK2 as an adverse prognostic biomarker in breast cancer by integrated bioinformatics and experimental analyses

PTK2 is highly expressed in many cancers and is involved in cell growth, survival, migration, and invasion. However, the prognostic value of PTK2 and its potential function remain unclear in breast cancer. Therefore, we performed a comprehensive analysis of multiple public databases to explore the r...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yanru, Wang, Wei, Fang, Lingyu, Zhang, Zhenyang, Deng, Shishan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751198/
https://www.ncbi.nlm.nih.gov/pubmed/36533074
http://dx.doi.org/10.3389/fmolb.2022.984564
_version_ 1784850420092370944
author Chen, Yanru
Wang, Wei
Fang, Lingyu
Zhang, Zhenyang
Deng, Shishan
author_facet Chen, Yanru
Wang, Wei
Fang, Lingyu
Zhang, Zhenyang
Deng, Shishan
author_sort Chen, Yanru
collection PubMed
description PTK2 is highly expressed in many cancers and is involved in cell growth, survival, migration, and invasion. However, the prognostic value of PTK2 and its potential function remain unclear in breast cancer. Therefore, we performed a comprehensive analysis of multiple public databases to explore the roles of PTK2. By integrating multiple datasets, we found that PTK2 mRNA expression in breast cancer tissue was higher than that in normal breast tissue or adjacent tissue. High PTK2 expression was associated with lymph node metastasis stage, tumor stage, breast cancer type, age, TP53 mutation, and gender and significantly predicted a poor survival outcome in breast cancer patients. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) results suggested that PTK2 and co-expressed genes participated in the cell cycle. Immune infiltration analysis clarified that high PTK2 expression was positively correlated with infiltrating levels of CD8(+) T cells, CD4(+) T cells, macrophages, neutrophils, and dendritic cells. The DNA methylation of PTK2 in breast cancer tissues was higher than that in normal tissues, and high PTK2 methylation was correlated with poor prognosis in breast cancer patients. Furthermore, 16 possible ceRNA networks related to PTK2 were constructed for breast cancer. Additionally, PTK2 knockdown could suppress the proliferation and migration ability of MCF-7 cells. These results suggest that PTK2 can be used as a prognostic biomarker for breast cancer.
format Online
Article
Text
id pubmed-9751198
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97511982022-12-16 Identification of PTK2 as an adverse prognostic biomarker in breast cancer by integrated bioinformatics and experimental analyses Chen, Yanru Wang, Wei Fang, Lingyu Zhang, Zhenyang Deng, Shishan Front Mol Biosci Molecular Biosciences PTK2 is highly expressed in many cancers and is involved in cell growth, survival, migration, and invasion. However, the prognostic value of PTK2 and its potential function remain unclear in breast cancer. Therefore, we performed a comprehensive analysis of multiple public databases to explore the roles of PTK2. By integrating multiple datasets, we found that PTK2 mRNA expression in breast cancer tissue was higher than that in normal breast tissue or adjacent tissue. High PTK2 expression was associated with lymph node metastasis stage, tumor stage, breast cancer type, age, TP53 mutation, and gender and significantly predicted a poor survival outcome in breast cancer patients. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) results suggested that PTK2 and co-expressed genes participated in the cell cycle. Immune infiltration analysis clarified that high PTK2 expression was positively correlated with infiltrating levels of CD8(+) T cells, CD4(+) T cells, macrophages, neutrophils, and dendritic cells. The DNA methylation of PTK2 in breast cancer tissues was higher than that in normal tissues, and high PTK2 methylation was correlated with poor prognosis in breast cancer patients. Furthermore, 16 possible ceRNA networks related to PTK2 were constructed for breast cancer. Additionally, PTK2 knockdown could suppress the proliferation and migration ability of MCF-7 cells. These results suggest that PTK2 can be used as a prognostic biomarker for breast cancer. Frontiers Media S.A. 2022-12-01 /pmc/articles/PMC9751198/ /pubmed/36533074 http://dx.doi.org/10.3389/fmolb.2022.984564 Text en Copyright © 2022 Chen, Wang, Fang, Zhang and Deng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Chen, Yanru
Wang, Wei
Fang, Lingyu
Zhang, Zhenyang
Deng, Shishan
Identification of PTK2 as an adverse prognostic biomarker in breast cancer by integrated bioinformatics and experimental analyses
title Identification of PTK2 as an adverse prognostic biomarker in breast cancer by integrated bioinformatics and experimental analyses
title_full Identification of PTK2 as an adverse prognostic biomarker in breast cancer by integrated bioinformatics and experimental analyses
title_fullStr Identification of PTK2 as an adverse prognostic biomarker in breast cancer by integrated bioinformatics and experimental analyses
title_full_unstemmed Identification of PTK2 as an adverse prognostic biomarker in breast cancer by integrated bioinformatics and experimental analyses
title_short Identification of PTK2 as an adverse prognostic biomarker in breast cancer by integrated bioinformatics and experimental analyses
title_sort identification of ptk2 as an adverse prognostic biomarker in breast cancer by integrated bioinformatics and experimental analyses
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751198/
https://www.ncbi.nlm.nih.gov/pubmed/36533074
http://dx.doi.org/10.3389/fmolb.2022.984564
work_keys_str_mv AT chenyanru identificationofptk2asanadverseprognosticbiomarkerinbreastcancerbyintegratedbioinformaticsandexperimentalanalyses
AT wangwei identificationofptk2asanadverseprognosticbiomarkerinbreastcancerbyintegratedbioinformaticsandexperimentalanalyses
AT fanglingyu identificationofptk2asanadverseprognosticbiomarkerinbreastcancerbyintegratedbioinformaticsandexperimentalanalyses
AT zhangzhenyang identificationofptk2asanadverseprognosticbiomarkerinbreastcancerbyintegratedbioinformaticsandexperimentalanalyses
AT dengshishan identificationofptk2asanadverseprognosticbiomarkerinbreastcancerbyintegratedbioinformaticsandexperimentalanalyses